Skip to main content
Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance

Drug Guidance

View all drug guidances and its details here.

159 articles

17 February 2025

Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

Condition

Cancer

Blood and Immune System

Drug guidance

17 February 2025

Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma

Condition

Cancer

Blood and Immune System

Drug guidance

17 February 2025

Deucravacitinib for moderate-to-severe chronic plaque psoriasis

Condition

Skin

Blood and Immune System

Drug guidance

17 February 2025

Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer

Condition

Cancer

Gynaecological

Drug guidance

17 February 2025

Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma

Condition

Cancer

Liver

Drug guidance

17 February 2025

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

Condition

Cancer

Blood and Immune System

Drug guidance

17 February 2025

Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma

Condition

Cancer

Gastrointestinal tract

Drug guidance

17 February 2025

Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer

Condition

Cancer

Respiratory

Drug guidance

17 February 2025

Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer

Condition

Cancer

Breast

Drug guidance

17 February 2025

Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

Condition

Cancer

Blood and Immune System

Drug guidance